Was suchen Sie?
Alle Filter
Therapiegebiete
Therapeutic Area
Veröffentlichungsdatum
Date published
Rectangle

02
bis
06
Juni 2023 Juni 2023
Stunden
09:00 AM - 06:00 PM
Ort
Chicago
Veranstalter:in
Novartis

Highlights from the ASCO congress 2023 for Ribociclib

Ribociclib

 

Resources related to Ribociclib 

Rectangle 4765
A subgroup analysis of the RIGHT Choice trial
A subgroup analysis of the RIGHT Choice trial

Outcomes with 1L ribociclib + ET vs. physician’s choice combination chemotherapy by age in pre/perimenopausal patients with aggressive HR+/HER2− aBC

See more details
Hide details
Rectangle 4765
A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58
A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58

Ribociclib vs. palbociclib in patients with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) aBC

See more details
Hide details

 

Abbreviations: 
1L: first line; ET: endocrine therapy; aBC: advanced breast cancer; HR+: hormone receptor positive, HER2− : human epidermal growth factor receptor 2 negative; AI: aromatase inhibitor; FUL: fulvestrant; ET: endocrine monotherapy, CT: chemotherapy